S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
OTCMKTS:IDRSF

Idorsia (IDRSF) Stock Price, News & Analysis

$2.64
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$2.64
$2.64
50-Day Range
$1.40
$2.64
52-Week Range
$1.40
$11.35
Volume
N/A
Average Volume
3,347 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
IDRSF stock logo

About Idorsia Stock (OTCMKTS:IDRSF)

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

IDRSF Stock Price History

IDRSF Stock News Headlines

Idorsia: Aprocitentan Approval Is A Vital News
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
Altcoin FRENZY Alert…
Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days…
Viatris, Idorsia Announce Global Research And Development Collaboration
Here's what to expect from Idorsia's earnings
Idorsia Shares Fall on Funding Needs
Idorsia reacquires the world-wide rights to aprocitentan
Idorsia Ltd (IDIA.SW)
Are Investors Undervaluing Idorsia Ltd (VTX:IDIA) By 38%?
Idorsia: Restructuring In Place
See More Headlines
Receive IDRSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:IDRSF
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. Jean-Paul Clozel M.D. (Age 69)
    CEO & Executive Director
    Comp: $1.57M
  • Mr. André C. Muller (Age 61)
    Executive VP & CFO
  • Dr. Martine Clozel (Age 69)
    Executive VP & Chief Scientific Officer
  • Mr. Andrew C. Weiss (Age 56)
    Senior VP and Head of Investor Relations & Corporate Communications
  • Mr. Julien Gander L.L.M. (Age 45)
    Senior VP, Group General Counsel & Company Secretary
  • Mr. Alexander Khatuntsev (Age 46)
    Senior VP & Head of Global Human Resources
  • Dr. Guy Braunstein M.D. (Age 68)
    Executive VP & Chief Medical Officer
  • Mr. Olivier Lambert (Age 58)
    Senior VP & Head of Technical Operations
  • Mr. Markus A. Riederer (Age 62)
    Senior VP & Head of Drug Discovery Biology
  • Mr. Christoph Boss (Age 56)
    Senior VP & Head of Drug Discovery Chemistry

IDRSF Stock Analysis - Frequently Asked Questions

Should I buy or sell Idorsia stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Idorsia in the last year. There are currently 4 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "strong sell" IDRSF shares.
View IDRSF analyst ratings
or view top-rated stocks.

How have IDRSF shares performed in 2024?

Idorsia's stock was trading at $2.45 on January 1st, 2024. Since then, IDRSF shares have increased by 7.8% and is now trading at $2.64.
View the best growth stocks for 2024 here
.

Are investors shorting Idorsia?

Idorsia saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 9,112,700 shares, a drop of 14.6% from the February 29th total of 10,667,300 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is currently 91,127.0 days.
View Idorsia's Short Interest
.

How do I buy shares of Idorsia?

Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IDRSF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners